Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:07:10.262Z.
Calculation as of: 2026-10-06T17:07:10.262Z.
Quote observation: 2026-10-06T17:04:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$64.56M
Price/OCF Ratio
N/A
TTM Avg
1.86
3Y Avg
1.86
5Y Avg
1.86
Market Cap
$63.78M
Price/OCF Ratio
N/A
TTM Avg
44.68
3Y Avg
44.68
5Y Avg
44.68
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $64.77M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.56M | N/A | 1.86 | 1.86 | 1.86 |
| InterCure Ltd. (INCR)vs › | $65.15M | 6.91 | 5.29 | 5.29 | 30.61 |
| RenovoRx, Inc. (RNXT)vs › | $64.20M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $65.46M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | N/A | 44.68 | 44.68 | 44.68 |
| XBiotech Inc. (XBIT)vs › | $65.85M | N/A | 4.25 | 4.25 | 4.25 |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $67.93M | 0.54 | 0.74 | 0.74 | 0.74 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2025-08-05 | 53.78 |
| 2025-08-04 | 54.03 |
| 2025-08-01 | 49.80 |
| 2025-07-31 | 50.79 |
| 2025-07-30 | 51.79 |
| 2025-07-29 | 48.80 |
| 2025-07-28 | 49.30 |
| 2025-07-25 | 45.81 |
| 2025-07-24 | 44.32 |
| 2025-07-23 | 46.56 |
| 2025-07-22 | 42.82 |
| 2025-07-21 | 43.57 |
| 2025-07-18 | 42.33 |
| 2025-07-17 | 42.58 |
| 2025-07-16 | 41.33 |
| 2025-07-15 | 36.10 |
| 2025-07-14 | 38.09 |
| 2025-07-11 | 33.86 |
| 2025-07-10 | 33.86 |
| 2025-07-09 | 33.86 |
| 2025-07-08 | 31.62 |
| 2025-07-07 | 31.12 |
| 2025-07-03 | 30.87 |
| 2025-07-02 | 30.13 |
| 2025-07-01 | 31.12 |
| 2025-06-30 | 30.62 |
| 2025-06-27 | 31.12 |
| 2025-06-26 | 32.37 |
| 2025-06-25 | 33.86 |
| 2025-06-24 | 34.36 |
| 2025-06-23 | 34.11 |
| 2025-06-20 | 35.85 |
| 2025-06-18 | 32.12 |
| 2025-06-17 | 30.87 |
| 2025-06-16 | 31.87 |
| 2025-06-13 | 30.87 |
| 2025-06-12 | 31.62 |
| 2025-06-11 | 32.12 |
| 2025-06-10 | 31.12 |
| 2025-06-09 | 33.11 |
| 2025-06-06 | 33.11 |
| 2025-06-05 | 31.37 |
| 2025-06-04 | 31.37 |
| 2025-06-03 | 30.38 |
| 2025-06-02 | 28.88 |
| 2025-05-30 | 27.64 |
| 2025-05-29 | 28.13 |
| 2025-05-28 | 28.88 |
| 2025-05-27 | 27.89 |
| 2025-05-23 | 29.88 |
| 2025-05-22 | 28.88 |
| 2025-05-21 | 28.63 |
| 2025-05-20 | 29.38 |
| 2025-05-19 | 27.14 |
| 2025-05-16 | 25.89 |
